Encore Vision's Acquisition

Encore Vision was acquired by Novartis on December 20, 2016.

Encore Vision (EV) develops EV06, a clinical-stage, disease-modifying topical therapy for presbyopia. EV06 comprises a proprietary small molecule prodrug, which works with the eye's endogenous enzymes…

Articles about Encore Vision's Acquisition: